Motohiro Hirao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Motohiro Hirao has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Hosui
Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, 1179-3 Nagasone-cho, Kita-ku, Sakai 591-8025, Osaka, Japan
6 shared publications - Kohsaku Ohnishi
Department of Gastroenterology and Hepatology Osaka Rosai Hospital Sakai Osaka Japan
4 shared publications - Takuya Yamada
Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, 1179-3 Nagasone-cho, Kita-ku, Sakai 591-8025, Osaka, Japan
4 shared publications - Hiroki Murai
Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, 1179-3 Nagasonecho, Kita Ward, Sakai 591-8025, Osaka, Japan
3 shared publications - Naoki Hiramatsu
Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, 1179-3 Nagasonecho, Kita Ward, Sakai 591-8025, Osaka, Japan
3 shared publications - Tomohide Kurahashi
Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, 1179-3 Nagasone-cho, Kita-ku, Sakai 591-8025, Osaka, Japan
3 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6769
Association Between CT Attenuation and Mechanical Basket Lithotripsy Failure in Common Bile Duct Stones: A Single-Centre Retrospective Exploratory Study
Background: Mechanical lithotripsy is used for difficult common bile duct (CBD) stones, but failure to fragment a grasped stone can complicate endoscopic management. Evidence regarding the association between preprocedural computed tomography (CT) attenuation and mechanical lithotripsy outcome is limited. This study explored the association between CT attenuation of CBD stones and mechanical basket lithotripsy failure in a single-centre retrospective cohort. Methods: We retrospectively analysed 37 patients in whom a CBD stone was grasped with a basket catheter, could not be extracted directly, and underwent attempted intraductal mechanical crushing between 1 April 2017 and 31 March 2023. Lithotripsy failure was defined as inability to fragment the grasped stone despite use of a dedicated crusher handle. Continuous variables were compared using the Mann–Whitney U test and categorical variables using Fisher’s exact test. CT attenuation analyses were restricted to CT-positive stones with measurable attenuation values (n = 27). Exploratory receiver operating characteristic (ROC) analyses were performed, and areas under the curve (AUCs) were accompanied by nonparametric bootstrap 95% confidence intervals (CIs) based on 10,000 resamples. No clinical CT attenuation threshold was proposed. Results: Mechanical lithotripsy succeeded in 31 patients and failed in 6. CT attenuation was measurable in 27 patients (21 successes and 6 failures). Among these patients, the failure group had higher mean CT attenuation than the success group (median 241 [IQR 217.8–473.5] HU vs. 76 [67–88] HU; p = 0.00064) and higher maximum CT attenuation (386 [269.8–589.3] HU vs. 123 [102–133] HU; p = 0.00133). Exploratory ROC analysis showed an AUC of 0.968 (bootstrap 95% CI, 0.871–1.000) for mean CT attenuation and 0.940 (bootstrap 95% CI, 0.800–1.000) for maximum CT attenuation. These estimates were derived and evaluated in the same small dataset and were therefore considered exploratory. Conclusions: In this small, selected retrospective cohort, higher CT attenuation values were observed among the six patients with mechanical basket lithotripsy failure. These findings are exploratory and require confirmation in larger prospective studies using standardized CT protocols before CT attenuation can be incorporated into procedural decision-making.
- 31 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (17) , 6769
Open AccessAssociation Between CT Attenuation and Mechanical Basket Lithotripsy Failure in Common Bile Duct Stones: A Single-Centre Retrospective Exploratory Study
Background: Mechanical lithotripsy is used for difficult common bile duct (CBD) stones, but failure to fragment a grasped stone can complicate endoscopic management. Evidence regarding the association between preprocedural computed tomography (CT) attenuation and mechanical lithotripsy outcome is limited. This study explored the association between CT attenuation of CBD stones and mechanical basket lithotripsy failure in a single-centre retrospective cohort. Methods: We retrospectively analysed 37 patients in whom a CBD stone was grasped with a basket catheter, could not be extracted directly, and underwent attempted intraductal mechanical crushing between 1 April 2017 and 31 March 2023. Lithotripsy failure was defined as inability to fragment the grasped stone despite use of a dedicated crusher handle. Continuous variables were compared using the Mann–Whitney U test and categorical variables using Fisher’s exact test. CT attenuation analyses were restricted to CT-positive stones with measurable attenuation values (n = 27). Exploratory receiver operating characteristic (ROC) analyses were performed, and areas under the curve (AUCs) were accompanied by nonparametric bootstrap 95% confidence intervals (CIs) based on 10,000 resamples. No clinical CT attenuation threshold was proposed. Results: Mechanical lithotripsy succeeded in 31 patients and failed in 6. CT attenuation was measurable in 27 patients (21 successes and 6 failures). Among these patients, the failure group had higher mean CT attenuation than the success group (median 241 [IQR 217.8–473.5] HU vs. 76 [67–88] HU; p = 0.00064) and higher maximum CT attenuation (386 [269.8–589.3] HU vs. 123 [102–133] HU; p = 0.00133). Exploratory ROC analysis showed an AUC of 0.968 (bootstrap 95% CI, 0.871–1.000) for mean CT attenuation and 0.940 (bootstrap 95% CI, 0.800–1.000) for maximum CT attenuation. These estimates were derived and evaluated in the same small dataset and were therefore considered exploratory. Conclusions: In this small, selected retrospective cohort, higher CT attenuation values were observed among the six patients with mechanical basket lithotripsy failure. These findings are exploratory and require confirmation in larger prospective studies using standardized CT protocols before CT attenuation can be incorporated into procedural decision-making.
- Open Access
Impact of Serum Albumin Levels on Prognosis and Recurrence in Patients with Hepatocellular Carcinoma
Background: Liver function is a critical factor, both in the selection of treatment and in the prediction of prognosis in patients with hepatocellular carcinoma (HCC). The ALBI grade, introduced as a more objective method of assessing liver function, utilizes serum albumin (Alb) and total bilirubin (Bil) levels. Although albumin is widely recognized for its role in maintaining colloid osmotic pressure and regulating plasma volume, recent studies have implicated it in tumor progression, invasion, and metastasis. The purpose of this study is to determine the impact of serum albumin levels on overall survival (OS) and tumor invasion/metastasis in HCC patients with the same liver function (ALBI grade) at the time of diagnosis. Methods: In this study, 285 patients diagnosed with primary HCC at our institution from 2015 to 2019 were classified by ALBI grade and analyzed. Among them, 78 patients with ALBI grade 2 status were selected to evaluate the impact of albumin level. To further isolate the effect of albumin rather than bilirubin, patients in the ALBI grade 2 cohort were divided into two groups based on mean values of Alb (3.5 g/dL) and Bil (1.0 mg/dL). Alb normal group (Group A): Alb ≥ 3.5 g/dL, Bil ≥ 1.0 mg/dL (n = 42). Bil normal group (Group T): Alb < 3.5 g/dL, Bil < 1.0 mg/dL (n = 36). Liver function was almost the same in these two groups based on the ALBI grade. OS, progression-free survival (PFS), types of recurrence, and pathological findings were compared between the two groups. OS was analyzed by the log-rank test, and comparisons between the two groups were performed by the t-test and chi-square test, with p < 0.05 indicating statistical significance. Results: OS was significantly worse in Group T than in Group A before and after propensity score matching based on age, performance status, and HCC stage (p < 0.001 and p = 0.011). Among the 44 patients who received curative treatment (surgery or radiofrequency ablation), OS was also significantly worse in Group T (p < 0.001). An analysis of the recurrence patterns of 44 curatively treated patients revealed that Group T had significantly shorter PFS (p < 0.001), and all recurrence patterns were multiple (p = 0.002). Pathological analysis in 28 surgical patients showed that serosal invasion was present in significantly more patients in Group T (p = 0.003). Conclusions: Low serum albumin levels in patients with HCC indicate both liver dysfunction and increased tumor invasion and metastasis. Nutritional support and albumin supplementation may help reduce intrahepatic metastases and improve prognosis. Further studies are needed to explore the underlying mechanisms and therapeutic potential.
Open AccessImpact of Serum Albumin Levels on Prognosis and Recurrence in Patients with Hepatocellular Carcinoma
Background: Liver function is a critical factor, both in the selection of treatment and in the prediction of prognosis in patients with hepatocellular carcinoma (HCC). The ALBI grade, introduced as a more objective method of assessing liver function, utilizes serum albumin (Alb) and total bilirubin (Bil) levels. Although albumin is widely recognized for its role in maintaining colloid osmotic pressure and regulating plasma volume, recent studies have implicated it in tumor progression, invasion, and metastasis. The purpose of this study is to determine the impact of serum albumin levels on overall survival (OS) and tumor invasion/metastasis in HCC patients with the same liver function (ALBI grade) at the time of diagnosis. Methods: In this study, 285 patients diagnosed with primary HCC at our institution from 2015 to 2019 were classified by ALBI grade and analyzed. Among them, 78 patients with ALBI grade 2 status were selected to evaluate the impact of albumin level. To further isolate the effect of albumin rather than bilirubin, patients in the ALBI grade 2 cohort were divided into two groups based on mean values of Alb (3.5 g/dL) and Bil (1.0 mg/dL). Alb normal group (Group A): Alb ≥ 3.5 g/dL, Bil ≥ 1.0 mg/dL (n = 42). Bil normal group (Group T): Alb < 3.5 g/dL, Bil < 1.0 mg/dL (n = 36). Liver function was almost the same in these two groups based on the ALBI grade. OS, progression-free survival (PFS), types of recurrence, and pathological findings were compared between the two groups. OS was analyzed by the log-rank test, and comparisons between the two groups were performed by the t-test and chi-square test, with p < 0.05 indicating statistical significance. Results: OS was significantly worse in Group T than in Group A before and after propensity score matching based on age, performance status, and HCC stage (p < 0.001 and p = 0.011). Among the 44 patients who received curative treatment (surgery or radiofrequency ablation), OS was also significantly worse in Group T (p < 0.001). An analysis of the recurrence patterns of 44 curatively treated patients revealed that Group T had significantly shorter PFS (p < 0.001), and all recurrence patterns were multiple (p = 0.002). Pathological analysis in 28 surgical patients showed that serosal invasion was present in significantly more patients in Group T (p = 0.003). Conclusions: Low serum albumin levels in patients with HCC indicate both liver dysfunction and increased tumor invasion and metastasis. Nutritional support and albumin supplementation may help reduce intrahepatic metastases and improve prognosis. Further studies are needed to explore the underlying mechanisms and therapeutic potential.
- Open Access
Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
Background/Objectives: Combination therapy with atezolizumab and bevacizumab (ATZ/BEV) is extremely effective and yields a high response rate in patients with hepatocellular carcinoma (HCC). In this study, the efficacy of adding locoregional therapy to ATZ/BEV in patients with stable disease (SD) HCC was investigated. Methods: One hundred five HCC patients who were treated with ATZ/BEV or lenvatinib (LEN) as first-line chemotherapy for unresectable HCC were evaluated on the basis of the modified RECIST criteria. SD patients whose initial antitumor effect was achieved received locoregional therapy, and the overall survival (OS) rate was assessed. Results: This study included 58 ATZ/BEV-treated participants and 47 LEN-treated participants. Twenty-eight SD patients (ATZ/BEV) and 20 SD patients (LEN) were identified. OS was significantly greater in ATZ/BEV-treated patients who also received locoregional therapy than in those who did not receive this additional therapy (p = 0.0343), whereas there was no difference between LEN-treated patients who also received locoregional therapy and those who did not. The locoregional therapy consisted of transcatheter arterial chemoembolization (TACE) and/or radiofrequency ablation (RFA). When assessing the add-on effect of TACE and/or RFA in the SD patients treated with ATZ/BEV, five patients were found to achieve CR. Conclusions: The addition of locoregional therapy, such as TACE/RFA, was found to affect SD patients. When a response is limited during ATZ/BEV therapy, it is important to consider the therapeutic option of adding locoregional therapy, as this additional treatment may contribute to improved prognosis via immune modulation.
Open AccessEfficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
Background/Objectives: Combination therapy with atezolizumab and bevacizumab (ATZ/BEV) is extremely effective and yields a high response rate in patients with hepatocellular carcinoma (HCC). In this study, the efficacy of adding locoregional therapy to ATZ/BEV in patients with stable disease (SD) HCC was investigated. Methods: One hundred five HCC patients who were treated with ATZ/BEV or lenvatinib (LEN) as first-line chemotherapy for unresectable HCC were evaluated on the basis of the modified RECIST criteria. SD patients whose initial antitumor effect was achieved received locoregional therapy, and the overall survival (OS) rate was assessed. Results: This study included 58 ATZ/BEV-treated participants and 47 LEN-treated participants. Twenty-eight SD patients (ATZ/BEV) and 20 SD patients (LEN) were identified. OS was significantly greater in ATZ/BEV-treated patients who also received locoregional therapy than in those who did not receive this additional therapy (p = 0.0343), whereas there was no difference between LEN-treated patients who also received locoregional therapy and those who did not. The locoregional therapy consisted of transcatheter arterial chemoembolization (TACE) and/or radiofrequency ablation (RFA). When assessing the add-on effect of TACE and/or RFA in the SD patients treated with ATZ/BEV, five patients were found to achieve CR. Conclusions: The addition of locoregional therapy, such as TACE/RFA, was found to affect SD patients. When a response is limited during ATZ/BEV therapy, it is important to consider the therapeutic option of adding locoregional therapy, as this additional treatment may contribute to improved prognosis via immune modulation.
- Open Access
- 9 February 2022
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 38, 102756
Significance of in vitro photodynamic cytodiagnosis with 5-aminolevulinic acid in biliary brush cytology for malignant biliary stricture
- 9 February 2022
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 38, 102756
Open AccessSignificance of in vitro photodynamic cytodiagnosis with 5-aminolevulinic acid in biliary brush cytology for malignant biliary stricture
- Open Access
- 14 January 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (2) , 294
Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed. However, it is still unclear whether this novel drug may improve long-term survival rates in cirrhotic patients with ascites. (2) Patients and methods: A total of 206 patients who responded insufficiently to conventional diuretics and were hospitalized for refractory ascites for the first time were retrospectively enrolled in this study. Among them, the first 57 consecutive patients were treated with conventional diuretics (the conventional therapy group); the latter 149 consecutive patients were treated with tolvaptan in addition to the conventional therapy (the tolvaptan group). (3) Results: The exacerbation of renal function was significantly milder in the tolvaptan group than in the conventional therapy group. The prognostic factors for survival in the tolvaptan group were being male, having hyperbilirubinemia, having a high blood urea nitrogen (BUN), and receiving high-dose furosemide at the start of tolvaptan treatment. The one-year and three-year cumulative survival rates were 67.8 and 45.3%, respectively, in patients with low-dose furosemide (p < 0.001). (4) Conclusion: Tolvaptan can improve survival in patients with cirrhotic ascites, especially when tolvaptan is started before high-dose furosemide administration.
- 14 January 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (2) , 294
Open AccessEarly Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed. However, it is still unclear whether this novel drug may improve long-term survival rates in cirrhotic patients with ascites. (2) Patients and methods: A total of 206 patients who responded insufficiently to conventional diuretics and were hospitalized for refractory ascites for the first time were retrospectively enrolled in this study. Among them, the first 57 consecutive patients were treated with conventional diuretics (the conventional therapy group); the latter 149 consecutive patients were treated with tolvaptan in addition to the conventional therapy (the tolvaptan group). (3) Results: The exacerbation of renal function was significantly milder in the tolvaptan group than in the conventional therapy group. The prognostic factors for survival in the tolvaptan group were being male, having hyperbilirubinemia, having a high blood urea nitrogen (BUN), and receiving high-dose furosemide at the start of tolvaptan treatment. The one-year and three-year cumulative survival rates were 67.8 and 45.3%, respectively, in patients with low-dose furosemide (p < 0.001). (4) Conclusion: Tolvaptan can improve survival in patients with cirrhotic ascites, especially when tolvaptan is started before high-dose furosemide administration.